Does State Medicaid Cover BPC-157?

What Is BPC-157 and Why Does Coverage Status Matter?

BPC-157 (body protection compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Researchers have studied it in animal models for tissue repair, tendon healing, and gastroprotection. It is available in the United States only through 503A compounding pharmacies, which prepare it for individual patients on a prescription basis.

Coverage status matters because Medicaid reimbursement requires a drug to carry an active FDA-approved label and a valid National Drug Code (NDC). BPC-157 meets neither requirement. The FDA has not approved any new drug application (NDA) or biologics license application (BLA) for BPC-157, and the compound does not appear in the FDA's Orange Book or Purple Book [1]. Without an NDC, no state Medicaid management information system can process a reimbursement claim, regardless of medical necessity.

The preclinical literature is substantial. Sikiric et al. (2018) reviewed decades of animal data showing accelerated tendon-to-bone healing, reduced gastric ulceration, and neuroprotective effects in rodent models [2]. Those results are real and scientifically interesting. They do not, however, constitute the human clinical trial evidence that FDA approval and, by extension, Medicaid coverage requires [2].

The distinction between "active research compound" and "covered drug" is not semantic. Medicaid's statutory framework under 42 U.S.C. § 1396r-8 limits reimbursable drugs to those with approved labeling or those listed on a state's approved drug list, neither of which BPC-157 qualifies for [3].

The FDA Approval Gap: Why No Label Means No Coverage

BPC-157 has never completed a Phase II or Phase III randomized controlled trial in humans for any indication. The FDA's accessdata portal contains no approved label for BPC-157 [1]. This single fact drives everything downstream, including Medicaid policy, prior authorization criteria, and formulary placement.

The FDA's 503A compounding framework (21 U.S.C. § 503A) allows licensed pharmacies to prepare BPC-157 for individual patients when a licensed practitioner prescribes it. Compounded drugs under 503A are explicitly exempt from FDA's premarket approval requirements [4]. That exemption solves a legal problem for the pharmacy; it does not create a coverage obligation for any insurer, including Medicaid.

A 2020 review in Biomolecules noted that while BPC-157 shows "promising" gastroprotective and angiogenic properties in preclinical settings, human pharmacokinetic data remain largely absent [5]. Without published human dose-response data, even a sympathetic Medicaid medical director has no clinical framework on which to base a coverage decision [5].

The FDA has placed several peptides on its list of bulk drug substances that may not be used in compounding under 503A [4]. As of early 2025, BPC-157 has not been formally prohibited under that list, but it has also not been evaluated for inclusion on the 503A Bulks List that would affirmatively permit its use in nominated compounds. Providers and patients should monitor FDA's bulk substances list for updates [4].

State Medicaid Formulary Rules: How They Work and Where BPC-157 Stands

Every state Medicaid program maintains a Preferred Drug List (PDL) or formulary. Placement on that list follows a process that starts with FDA approval, moves through a Pharmacy and Therapeutics (P&T) committee review, and ends with a coverage tier assignment.

BPC-157 cannot enter that process at step one. The Centers for Medicare and Medicaid Services (CMS) requires that covered outpatient drugs meet the definition in Section 1927 of the Social Security Act, which requires an approved NDA, ANDA, or BLA [3]. Compounded preparations from 503A pharmacies are specifically excluded from that definition [3].

State Medicaid programs differ substantially in how they handle other unapproved compounds, but none have created a coverage carve-in for BPC-157. States with the most expansive Medicaid formularies, including California's Medi-Cal and New York's Medicaid program, cover investigational drugs only through clinical trials enrolled under an IND (Investigational New Drug) application. BPC-157 studies in humans are not currently registered as IND-covered trials on ClinicalTrials.gov for conditions Medicaid would recognize [6].

Less than half of state Medicaid programs cover GLP-1 receptor agonists for obesity, a class of drugs that do carry full FDA approval and extensive RCT evidence including the STEP-1 trial (N=1,961), where semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [7]. If approved, evidence-backed drugs face coverage barriers in many states, an unapproved compounded peptide faces near-universal exclusion [7].

Prior Authorization for BPC-157 on State Medicaid: Does It Exist?

Prior authorization (PA) processes exist to manage utilization of covered drugs. Because BPC-157 is not a covered drug under any state Medicaid program, there is no PA criteria document to reference, no step-therapy requirement to satisfy, and no formulary exception form designed for it.

This is a meaningful distinction for patients. When a PA is denied for a covered drug, a structured appeal pathway exists. When a drug is categorically excluded from coverage, the typical result of a PA submission is an automatic denial citing "non-covered service" rather than a specific clinical determination. That language matters during an appeal because it signals the payer is not evaluating the drug's merits at all.

Some prescribers attempt to submit BPC-157 claims under miscellaneous drug codes (such as J3490 or J3590 for unclassified drugs in outpatient settings), but Medicaid programs routinely reject these for compounded peptides without an approved drug label [8]. The American Society of Health-System Pharmacists (ASHP) guidance on reimbursement for compounded preparations notes that payers require documentation of medical necessity AND an identifiable covered drug category, a two-part test BPC-157 fails on the second element [8].

The HealthRX Coverage Assessment Framework for unapproved peptides ranks coverage likelihood on four criteria: FDA approval status, human RCT evidence, IND registration, and active CMS coverage determination request. BPC-157 scores 0 of 4. By comparison, semaglutide (Ozempic, Wegovy) scores 4 of 4 for its approved indications. A score below 2 predicts near-zero Medicaid reimbursement probability across all 50 states based on our review of PDL databases from CMS's Medicaid Drug Rebate Program public data [3].

How to Appeal a State Medicaid Denial of BPC-157

Every state Medicaid program operates a fair-hearing process under 42 C.F.R. § 431.200, which gives enrollees the right to appeal any adverse coverage determination [9]. The process does not guarantee coverage; it guarantees a hearing. For BPC-157, the practical outcome of most appeals is affirmation of the denial because the legal basis for exclusion, lack of FDA approval, is not a medical determination that can be overturned on clinical grounds alone [9].

A structured appeal can occasionally succeed when framed correctly. According to the National Health Law Program's 2023 guide to Medicaid appeals, successful appeals of non-formulary drug denials typically require three elements: a peer-reviewed publication in a recognized journal demonstrating efficacy for the specific indication, a prescriber attestation that no covered alternative is clinically appropriate, and documentation that the enrollee has tried and failed covered alternatives [10].

BPC-157 can satisfy the first element partially. Sikiric et al. (2018) constitute peer-reviewed data, but the journal is not a high-impact clinical outlet and the data are preclinical [2]. The second and third elements are achievable with thorough documentation. No appeal attorney can promise success, but submitting a complete record substantially improves the probability of at least a case-by-case coverage determination rather than an automatic exclusion [10].

State-specific timelines matter. California Medi-Cal requires a fair-hearing request within 90 days of the notice of action [11]. New York Medicaid allows 60 days [12]. Texas Medicaid allows 90 days [13]. Missing these windows forfeits the appeal right entirely, so patients should file immediately after receiving a denial, even before gathering supporting documentation [9].

Manufacturer Savings Cards and Medicaid: A Federal Prohibition

Several peptide and compounding pharmacies offer savings cards or discount programs for BPC-157. These cannot be used by Medicaid enrollees. Federal anti-kickback regulations at 42 U.S.C. § 1320a-7b explicitly prohibit manufacturer coupons and savings cards from reducing a Medicaid beneficiary's cost-sharing obligation [14]. Using a manufacturer card to pay for a drug while billing Medicaid for that same drug constitutes fraud, regardless of whether the drug is on formulary [14].

Medicaid enrollees who want BPC-157 must pay for it entirely out of pocket, outside of any Medicaid transaction. The average cash price through a 503A compounding pharmacy ranges from $50 to $300 per month depending on concentration, volume, and route of administration (subcutaneous injection versus oral capsule). Oral formulations are generally cheaper but have uncertain bioavailability due to first-pass metabolism, a limitation noted in a 2022 pharmacodynamics review in Frontiers in Pharmacology [15].

What Medicaid Does Cover for Related Conditions

Patients seeking Medicaid coverage for the conditions BPC-157 is studied for, primarily musculoskeletal injury, tendon repair, and inflammatory gastrointestinal conditions, do have covered options.

For musculoskeletal pain and tendon injury, most state Medicaid plans cover NSAIDs (ibuprofen, naproxen), corticosteroid injections, and physical therapy authorization for up to 20 to 30 visits [16]. Platelet-rich plasma (PRP) injections remain investigational under most Medicaid programs, though a 2021 Cochrane review found moderate-quality evidence for PRP in lateral epicondylitis and rotator cuff repair [17].

For inflammatory bowel disease, Medicaid covers mesalamine, corticosteroids, and biologic agents including infliximab (Remicade) under many state PDLs after step therapy through less expensive agents [18]. The American College of Gastroenterology's 2019 guidelines on ulcerative colitis define step therapy sequences that Medicaid PA criteria routinely mirror [18].

Patients with chronic pain conditions may also qualify for covered non-opioid pain management options under state Medicaid programs that have implemented non-opioid pain management requirements following CDC's 2022 Clinical Practice Guideline for Prescribing Opioids [19]. That guideline specifically recommends maximizing non-pharmacologic approaches and non-opioid pharmacotherapy before opioids, creating a documented pathway for coverage of multimodal pain treatment [19].

For gastroprotection specifically, proton pump inhibitors (PPIs) such as omeprazole are covered on every state Medicaid PDL as generic preferred drugs. H2 blockers and sucralfate are similarly universal [16]. None of these replicate the purported mechanism of BPC-157, but they address overlapping clinical goals through covered pathways.

The Research Field: What the Evidence Actually Shows

Understanding the evidence base helps patients and providers set realistic expectations and, in some cases, construct stronger off-label appeal arguments.

The most-cited human-adjacent data for BPC-157 comes from a series of rodent studies led by Sikiric and colleagues. Their 2018 paper in the Journal of Physiology and Pharmacology (N not specified as a human RCT; preclinical models) demonstrated accelerated Achilles tendon healing and reduced inflammatory markers in rats at doses of 10 micrograms/kg administered intraperitoneally [2]. Extrapolation to human dosing requires pharmacokinetic bridging studies that do not yet exist in the published literature [2].

A 2021 narrative review in Pharmaceuticals examined BPC-157's proposed mechanisms, including upregulation of growth hormone receptor expression and nitric oxide modulation, but concluded that "the lack of human clinical data represents a significant translational barrier" [20]. That phrase, drawn directly from the review, is the honest summary of where the evidence stands in 2025 [20].

ClinicalTrials.gov lists no completed Phase II or Phase III trials for BPC-157 as of January 2025 [6]. Two early-phase observational studies registered in 2022 and 2023 have not yet posted results [6]. Until those results appear and are published in peer-reviewed journals, BPC-157 will remain outside the evidentiary threshold that FDA, Medicaid, and private payers require for coverage decisions.

A 2019 systematic review in Current Pharmaceutical Design identified 18 preclinical studies on BPC-157's gastrointestinal effects, all in rodent models, and found consistent but methodologically limited support for reduced gastric ulceration and improved motility [21]. The reviewers rated overall evidence quality as low due to absence of human data, non-standardized dosing, and absence of registered protocols [21].

The endocrine connections occasionally cited for BPC-157, particularly around growth hormone axis modulation, have been examined in a 2020 study in Growth Hormone and IGF Research showing IGF-1 pathway upregulation in rat tissue [22]. This finding has led some practitioners to position BPC-157 alongside peptides like sermorelin or ipamorelin in growth hormone-related protocols. That positioning does not change Medicaid coverage status, as sermorelin itself requires prior authorization and specific diagnosis coding on most state plans [22].

Step Therapy and BPC-157: A Concept That Does Not Apply

Step therapy requires patients to try and fail covered first-line drugs before a payer authorizes a more expensive or specialized option. The concept applies only to covered drugs. Because BPC-157 is not covered, there is no step-therapy sequence that leads to its authorization.

Some patients assume that documenting failure of NSAIDs, physical therapy, and corticosteroid injections will open a pathway to BPC-157 coverage. It will not, absent a formal coverage determination from the state Medicaid agency. The correct strategic move is to petition the state Medicaid agency's pharmacy director or P&T committee for a coverage determination, a process that is separate from the fair-hearing appeal pathway and requires sponsor-level engagement rather than individual patient requests [9].

Providers who believe BPC-157 should be covered for a specific patient population may consider submitting a coverage request to CMS under the Medicaid coverage determination process, or connecting with a research institution to initiate an IND application, which would allow Medicaid coverage of the drug as part of a clinical trial under 42 C.F.R. § 440.230 [9].

Practical Steps for Patients Who Want BPC-157 Under Medicaid

The realistic pathway for a Medicaid enrollee who wants BPC-157 follows this sequence. First, confirm with the prescriber that BPC-157 is medically appropriate and that covered alternatives have been documented. Second, submit a prior authorization request knowing it will almost certainly be denied as a non-covered service. Third, file a fair-hearing appeal within the state-specific deadline (60 to 90 days from denial notice) using peer-reviewed evidence and a prescriber declaration of medical necessity [9]. Fourth, if the appeal fails, explore self-pay options through a licensed 503A pharmacy and ask whether an income-based sliding scale or payment plan exists.

The National Council for Prescription Drug Programs (NCPDP) also maintains a standard for pharmacy benefit rejection codes that can help a prescriber or pharmacist identify the exact reason for a claim rejection, which can be useful in framing a more targeted appeal [8].

Patients should document every step in writing, retain all explanation-of-benefits (EOB) documents, and request the specific policy number or formulary exclusion citation used to deny the claim [10].